Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cescon, Dave
KAN-HER2 MRD, NCT05388149: Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease	Recruiting	2	15	Canada	Neratinib, NERLYNX	University Health Network, Toronto	Breast Cancer, HER2-positive Breast Cancer	07/26	07/26